Followers | 74 |
Posts | 3281 |
Boards Moderated | 0 |
Alias Born | 03/16/2014 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, January 24, 2019 1:17:55 PM
Brain tumour patients to receive immunotherapy for first time on the NHS
ROSS LYDALL Health Editor
1 day ago
The Evening Standard
Campaigner: Tessa Jowell called for better access to new therapies ( Lucy Young )
ES News Emai
Patients with the same deadly brain tumour suffered by Tessa Jowell are starting to receive immunotherapy on the NHS for the first time.
A landmark trial has opened at the National Hospital for Neurology and Neurosurgery in Bloomsbury for people with glioblastoma.
Baroness Jowell, the former Olympics minister, had surgery there and campaigned for greater access to innovative therapies prior to her death last May.
The trial, described as the most important for brain cancer in 15 years, recruited the first of 120 patients last week. Drugs firm Bristol-Myers Squibb is donating £6 million worth of ipilimumab, while the National Brain Appeal is halfway towards raising £250,000 to cover the trial’s administration costs.
Former headteacher Bernice McCabe, who received ipilimumab as a private patient after being diagnosed with a brain tumour last year, told the Standard: “I’m delighted to hear that the immunotherapy clinical trial is now recruiting patients.”
Eighty patients will receive ipilimumab in addition to the standard treatment of surgery followed by radiotherapy and chemotherapy. Forty will be in the “control group” and undergo surgery, radiotherapy and chemotherapy. Trial leader Dr Paul Mulholland said: “As clinicians we have had no new treatment options for patients with glioblastoma for well over a decade. There is an urgent need for new treatments to improve clinical outcomes and survival.
“When using ipilimumab previously in brain cancer patients we have seen, in some patients, some dramatic and exciting responses. The aim of this clinical trial is to see if these responses lead to improved life expectancy.” Mrs McCabe, 65, co-director of Prince Charles’s education institute, stepped down as head of North London Collegiate School in Edgware after 20 years in 2017.
She said: “I feel very lucky to have been able to receive this treatment due to having private health insurance.
“It felt important to me to support the National Brain Appeal’s fundraising to work towards making this available to NHS patients with glioblastoma.”
Glioblastoma is the most common type of brain tumour. About 2,200 cases a year are diagnosed in England. Average survival is less than a year. Six other NHS hospitals will take part in the trial, which is open to UK residents.
The treatment involves four infusions over 12 weeks. Each infusion, if given privately, would cost between £25,000 and £35,000. The drug makes the immune system more active, enabling it to destroy cancer cells.
Donate to the immunotherapy fund at justgiving.com/campaigns/charity/tnba/immunotherapy
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM